- Home
- PACB vs ENGN Comparison
PACB vs ENGN Comparison
Compare PACB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- ENGN
- Stock Information
- Founded
- PACB 2000
- ENGN 1999
- Country
- PACB United States
- ENGN Canada
- Employees
- PACB N/A
- ENGN N/A
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- ENGN
- Sector
- PACB Industrials
- ENGN
- Exchange
- PACB Nasdaq
- ENGN Nasdaq
- Market Cap
- PACB 364.2M
- ENGN 297.7M
- IPO Year
- PACB 2010
- ENGN N/A
- Fundamental
- Price
- PACB $1.33
- ENGN $5.25
- Analyst Decision
- PACB Buy
- ENGN Buy
- Analyst Count
- PACB 13
- ENGN 9
- Target Price
- PACB $2.79
- ENGN $25.89
- AVG Volume (30 Days)
- PACB 14.6M
- ENGN 56.3K
- Earning Date
- PACB 02-13-2025
- ENGN 03-18-2025
- Dividend Yield
- PACB N/A
- ENGN N/A
- EPS Growth
- PACB N/A
- ENGN N/A
- EPS
- PACB N/A
- ENGN N/A
- Revenue
- PACB $154,014,000.00
- ENGN N/A
- Revenue This Year
- PACB $9.91
- ENGN N/A
- Revenue Next Year
- PACB $28.57
- ENGN N/A
- P/E Ratio
- PACB N/A
- ENGN N/A
- Revenue Growth
- PACB N/A
- ENGN N/A
- 52 Week Low
- PACB $1.16
- ENGN $4.42
- 52 Week High
- PACB $4.57
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- PACB 40.23
- ENGN 34.69
- Support Level
- PACB $1.46
- ENGN $5.14
- Resistance Level
- PACB $1.68
- ENGN $5.98
- Average True Range (ATR)
- PACB 0.16
- ENGN 0.62
- MACD
- PACB -0.02
- ENGN -0.04
- Stochastic Oscillator
- PACB 8.11
- ENGN 5.91
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.